Investigator Kidist Yimam, MD

Seladelpar in Subjects With Primary Biliary Cholangitis (PBC)

Investigators: Edward Holt MD, Raphael Merriman MD, Kidist Yimam MD

Status: Active, Recruiting

Phase 3 Study to Evaluate the Efficacy and Safety of Peginterferon Lambda for 48 Weeks in Patients With Chronic HDV (LIMT-2)

Investigators: Stewart Cooper M.D., Raphael Merriman MD, Kidist Yimam MD

Status: Active, Recruiting

Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) (ELATIVE)

Investigators: Edward Holt MD, Raphael Merriman MD, Kidist Yimam MD

Status: Active, Recruiting

A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC) (VIST

Investigators: Edward Holt MD, Raphael Merriman MD, Kidist Yimam MD

Status: Active, Recruiting

Phase 2a Evaluation of Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Patients With Primary Sclerosing Cholangitis (PSC)

Investigators: Edward Holt MD, Kidist Yimam MD

Status: Active, Recruiting

Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Adults With Primary Sclerosing Cholangitis (PRIMIS)

Investigators: Edward Holt MD, Kidist Yimam MD

Status: Active, Not Recruiting

RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA

Investigators: Edward Holt MD, Raphael Merriman MD, Kidist Yimam MD

Status: Active, Recruiting